CorMedix Inc. (CRMD) shareholders
Close on Nov 17, 2026Market cap $364.00MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (7.94%), David Kroin (7.94%) | 6,274,076 | 7.94% | 13G (passive) amendment | Mar 31, 2026 |
| Shaibatalhamd Aymen Abdalkader | 4,618,511 | 5.90% | 13G (passive) amendment | Jun 11, 2026 |
| BlackRock, Inc. | 4,567,897 | 7.50% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,324,111 | 8.11% | $49.64M | +356,536 | 0.00% |
| Deep Track Capital, LP | 6,274,076 | 8.05% | $49.25M | – | 0.72% |
| Vanguard Capital Management LLC | 3,135,075 | 4.02% | $24.61M | +5,419 | 0.00% |
| State Street Corp | 2,316,845 | 2.97% | $18.19M | +125,002 | 0.00% |
| Royce & Associates LP | 2,176,362 | 2.79% | $17.08M | +288,830 | 0.14% |
| Geode Capital Management, LLC | 1,947,014 | 2.50% | $15.29M | +130,107 | 0.00% |
| UBS Group AG | 1,877,940 | 2.41% | $14.74M | +339,695 | 0.00% |
| Oberweis Asset Management Inc/ | 1,323,915 | 1.70% | $10.39M | +112,800 | 0.21% |
| Alyeska Investment Group, L.P. | 850,000 | 1.09% | $6.67M | – | 0.02% |
| Marshall Wace, Llp | 779,535 | 1.00% | $6.12M | +276,570 | 0.00% |
| Northern Trust Corp | 756,430 | 0.97% | $5.94M | +118,747 | 0.00% |
| Vanguard Portfolio Management LLC | 708,604 | 0.91% | $5.56M | −33,967 | 0.00% |
| Pacer Advisors, Inc. | 633,978 | 0.81% | $4.98M | +53,358 | 0.01% |
| Hrt Financial LP | 625,558 | 0.80% | $4.91M | +333,113 | 0.00% |
| Trexquant Investment LP | 623,797 | 0.80% | $4.90M | +63,160 | 0.03% |
| Charles Schwab Investment Management Inc | 618,172 | 0.79% | $4.85M | +15,206 | 0.00% |
| Armistice Capital, LLC | 500,000 | 0.64% | $3.93M | New | 0.05% |
| Vanguard Fiduciary Trust Co | 484,322 | 0.62% | $3.80M | −21,357 | 0.00% |
| Goldman Sachs Group Inc | 466,393 | 0.60% | $3.66M | −44,936 | 0.00% |
| Raymond James Financial Inc | 446,142 | 0.57% | $3.50M | +117,918 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 194 | 44M | 56.5% | 30 / 68 | 59 / 21 | 6M | 3M |
| Q1 2026 | 188 | 41M | 52.8% | 44 / 55 | 60 / 49 | 13M | 9M |
| Q4 2025 | 199 | 42M | 53.8% | 39 / 78 | 57 / 28 | 11M | 12M |
| Q3 2025 | 190 | 43M | 55.5% | 51 / 91 | 28 / 33 | 15M | 6M |
| Q2 2025 | 172 | 34M | 44.0% | 52 / 62 | 36 / 14 | 15M | 4M |
| Q1 2025 | 136 | 24M | 30.2% | 27 / 50 | 34 / 17 | 4M | 4M |
| Q4 2024 | 129 | 23M | 29.5% | 40 / 49 | 24 / 11 | 7M | 3M |
| Q3 2024 | 102 | 19M | 24.8% | 19 / 38 | 22 / 15 | 8M | 3M |
| Q2 2024 | 99 | 17M | 22.0% | 18 / 37 | 22 / 9 | 2M | 2M |
| Q1 2024 | 90 | 18M | 22.7% | 8 / 24 | 33 / 19 | 1M | 2M |
| Q4 2023 | 101 | 19M | 24.4% | 17 / 37 | 20 / 8 | 2M | 1M |
| Q3 2023 | 92 | 18M | 23.0% | 18 / 34 | 21 / 12 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
146 funds held CRMD in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CRMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,227,723 | 2.86% | $17.49M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,939,160 | 2.49% | $15.22M | 0.02% | Jun 30, 2026 |
| Oberweis Micro-Cap Fund | 1,277,200 | 1.64% | $10.03M | 0.62% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 824,083 | 1.06% | $6.47M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 816,503 | 1.05% | $6.15M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 683,402 | 0.88% | $5.36M | 0.04% | Jun 30, 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 626,124 | 0.80% | $4.71M | 0.13% | Jul 31, 2026 |
| Royce Small-Cap Opportunity Fund | 566,897 | 0.73% | $4.45M | 0.32% | Jun 30, 2026 |
| Royce Small-Cap Fund | 562,746 | 0.72% | $4.42M | 0.21% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 549,805 | 0.71% | $4.32M | 1.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 381,249 | 0.49% | $3.22M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 381,233 | 0.49% | $3.22M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 347,750 | 0.45% | $2.94M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 250,705 | 0.32% | $1.97M | 0.13% | Jun 30, 2026 |
| Royce Capital Fund - Small-Cap Portfolio | 245,212 | 0.31% | $1.92M | 1.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joseph Todisco | Chief Executive Officer, Director | 854,749 | 1.10% | Nov 16, 2026 |
| Kaufman Beth Zelnick | Chief Legal Officer | 260,684 | 0.33% | Sep 1, 2026 |
| Elizabeth Hurlburt | Chief Operating Officer | 270,463 | 0.35% | Sep 1, 2026 |
| Susan Blum | Chief Financial Officer | 124,315 | 0.16% | Sep 1, 2026 |
| Michael David Seckler | Chief Commercial Officer | 133,156 | 0.17% | Jan 15, 2026 |
| Matthew T. David | Chief Financial Officer | 95,270 | 0.12% | Jan 14, 2025 |
| Erin Mistry | EVP, Chief Commercial Officer | 100,992 | 0.13% | Jan 14, 2025 |
| Janet Dillione | Director | 117,835 | 0.15% | Sep 18, 2026 |
| Robert A. Stewart | Director | 66,453 | 0.09% | Jan 27, 2026 |
| Myron Kaplan | Director | 261,487 | 0.34% | Jan 27, 2026 |
| Gregory Scott Duncan | Director | 68,786 | 0.09% | Jan 27, 2026 |
| Steven W. Lefkowitz | Director | 158,103 | 0.20% | Jan 27, 2026 |
| Alan W. Dunton | Director | 70,703 | 0.09% | Jan 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph Todisco Chief Executive Officer, Director | Nov 13, 2026 | Buy | +80,000 | $4.89 | $391.20K | 854,749 |
| Janet Dillione Director | Sep 18, 2026 | Option exercise | +48,909 | – | – | 117,835 |
| Susan Blum Chief Financial Officer | Aug 29, 2026 | Tax withholding | −8,424 | $8.30 | $69.92K | 124,315 |
| Elizabeth Hurlburt Chief Operating Officer | Aug 29, 2026 | Tax withholding | −8,076 | $8.30 | $67.03K | 270,463 |
| Kaufman Beth Zelnick Chief Legal Officer | Aug 29, 2026 | Tax withholding | −8,424 | $8.30 | $69.92K | 260,684 |
| Elizabeth Hurlburt Chief Operating Officer | Feb 4, 2026 | Award | +36,006 | – | – | 278,539 |
| Joseph Todisco Chief Executive Officer, Director | Feb 4, 2026 | Award | +77,156 | – | – | 774,749 |
| Kaufman Beth Zelnick Chief Legal Officer | Feb 4, 2026 | Award | +36,006 | – | – | 269,108 |
| Gregory Scott Duncan Director | Jan 26, 2026 | Award | +30,453 | – | – | 68,786 |
| Janet Dillione Director | Jan 26, 2026 | Award | +30,453 | – | – | 68,926 |
| Robert A. Stewart Director | Jan 26, 2026 | Award | +30,453 | – | – | 66,453 |
| Steven W. Lefkowitz Director | Jan 26, 2026 | Award | +30,453 | – | – | 125,951 |
| Alan W. Dunton Director | Jan 26, 2026 | Award | +30,453 | – | – | 70,703 |
| Myron Kaplan Director | Jan 26, 2026 | Award | +30,453 | – | – | 231,487 |
| Elizabeth Hurlburt Chief Operating Officer | Jan 23, 2026 | Award | +93,010 | – | – | 253,311 |
| Elizabeth Hurlburt Chief Operating Officer | Jan 23, 2026 | Tax withholding | −10,778 | $7.27 | $78.36K | 242,533 |
| Susan Blum Chief Financial Officer | Jan 23, 2026 | Award | +72,820 | – | – | 142,506 |
| Susan Blum Chief Financial Officer | Jan 23, 2026 | Tax withholding | −9,767 | $7.27 | $71.01K | 132,739 |
| Joseph Todisco Chief Executive Officer, Director | Jan 23, 2026 | Tax withholding | −27,306 | $7.27 | $198.51K | 697,593 |
| Joseph Todisco Chief Executive Officer, Director | Jan 23, 2026 | Award | +225,900 | – | – | 724,899 |
| Kaufman Beth Zelnick Chief Legal Officer | Jan 23, 2026 | Award | +72,820 | – | – | 241,905 |
| Kaufman Beth Zelnick Chief Legal Officer | Jan 23, 2026 | Tax withholding | −8,803 | $7.27 | $64.00K | 233,102 |
| Janet Dillione Director | Jan 21, 2026 | Sale(10b5-1 plan) | −10,000 | $6.88 | $68.80K | 38,473 |
| Joseph Todisco Chief Executive Officer, Director | Jan 17, 2026 | Tax withholding | −22,665 | $6.78 | $153.67K | 498,999 |
| Joseph Todisco Chief Executive Officer, Director | Jan 16, 2026 | Option exercise | +29,585 | $3.38 | $100.00K | 521,664 |
| Elizabeth Hurlburt Chief Operating Officer | Jan 12, 2026 | Tax withholding | −5,794 | $7.15 | $41.43K | 160,301 |
| Joseph Todisco Chief Executive Officer, Director | Jan 12, 2026 | Tax withholding | −17,417 | $7.15 | $124.53K | 492,079 |
| Steven W. Lefkowitz Director | Jan 12, 2026 | Option exercise | +15,000 | $5.63 | $84.45K | 95,498 |
| Michael David Seckler Chief Commercial Officer | Jan 8, 2026 | Award | +133,156 | – | – | 133,156 |
| Elizabeth Hurlburt Chief Operating Officer | Jan 2, 2026 | Tax withholding | −10,895 | $12.16 | $132.48K | 166,095 |
| Kaufman Beth Zelnick Chief Legal Officer | Jan 2, 2026 | Tax withholding | −11,333 | $12.16 | $137.81K | 169,085 |
| Alan W. Dunton Director | Dec 30, 2025 | Sale(10b5-1 plan) | −20,000 | $13.00 | $260.00K | 40,250 |
| Alan W. Dunton Director | Dec 30, 2025 | Option exercise | +20,000 | $4.03 | $80.60K | 60,250 |
| Joseph Todisco Chief Executive Officer, Director | Dec 18, 2025 | Sale(10b5-1 plan) | −30,000 | $12.00 | $360.00K | 509,496 |
| Joseph Todisco Chief Executive Officer, Director | Dec 18, 2025 | Option exercise | +30,000 | $4.43 | $132.90K | 539,496 |
| Janet Dillione Director | Dec 9, 2025 | Sale(10b5-1 plan) | −34,000 | $12.00 | $408.00K | 48,473 |
| Janet Dillione Director | Dec 9, 2025 | Option exercise | +19,000 | $9.55 | $181.45K | 67,473 |
| Janet Dillione Director | Dec 9, 2025 | Option exercise | +15,000 | $5.63 | $84.45K | 82,473 |
| Steven W. Lefkowitz Director | Dec 9, 2025 | Sale | −40,000 | $11.88 | $475.20K | 80,498 |
| Janet Dillione Director | Dec 2, 2025 | Option exercise | +19,323 | $3.55 | $68.60K | 95,130 |
| Janet Dillione Director | Dec 2, 2025 | Option exercise | +15,124 | $4.43 | $67.00K | 75,807 |
| Janet Dillione Director | Dec 2, 2025 | Option exercise | +12,210 | $4.03 | $49.21K | 60,683 |
| Janet Dillione Director | Dec 2, 2025 | Sale(10b5-1 plan) | −46,657 | $10.00 | $466.57K | 48,473 |
| Janet Dillione Director | Nov 24, 2025 | Sale | −26,343 | $9.93 | $261.59K | 48,473 |
| Janet Dillione Director | Nov 24, 2025 | Option exercise | +8,000 | $2.85 | $22.80K | 56,473 |
| Janet Dillione Director | Nov 24, 2025 | Option exercise | +4,876 | $4.43 | $21.60K | 69,139 |
| Janet Dillione Director | Nov 24, 2025 | Option exercise | +5,677 | $3.55 | $20.15K | 74,816 |
| Janet Dillione Director | Nov 24, 2025 | Option exercise | +7,790 | $4.03 | $31.39K | 64,263 |
| Janet Dillione Director | Nov 14, 2025 | Sale | −30,000 | $11.42 | $342.60K | 48,473 |
| Myron Kaplan Director | Oct 23, 2025 | Buy | +25,000 | $11.02 | $275.50K | 201,034 |
| Gregory Scott Duncan Director | Sep 16, 2025 | Option exercise | +13,333 | $8.32 | $110.93K | 38,333 |
| Alan W. Dunton Director | Sep 12, 2025 | Sale | −10,000 | $13.13 | $131.30K | 40,250 |
| Alan W. Dunton Director | Sep 12, 2025 | Option exercise | +10,000 | $3.55 | $35.50K | 50,250 |
| Joseph Todisco Chief Executive Officer | Sep 12, 2025 | Option exercise | +50,000 | $3.47 | $173.50K | 559,496 |
| Joseph Todisco Chief Executive Officer | Sep 12, 2025 | Sale | −50,000 | $13.00 | $650.00K | 509,496 |
| Elizabeth Hurlburt Chief Operating Officer | Sep 11, 2025 | Sale | −41,121 | $13.08 | $537.86K | 176,990 |
| Elizabeth Hurlburt Chief Operating Officer | Sep 11, 2025 | Option exercise | +41,121 | $1.45 | $59.63K | 218,111 |
| Elizabeth Hurlburt Chief Operating Officer | Sep 9, 2025 | Option exercise | +12,876 | $1.45 | $18.67K | 189,866 |
| Elizabeth Hurlburt Chief Operating Officer | Sep 9, 2025 | Sale | −12,876 | $13.51 | $173.95K | 176,990 |
| Kaufman Beth Zelnick Chief Legal Officer | Sep 9, 2025 | Sale | −400 | $12.82 | $5.13K | 180,418 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CorMedix's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,690 shares on Sep 16, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Janet Dillione Director | Jan 21, 2026 | 10,000 | $68.50K | Jan 21, 2026 | Stock Plan Activity |
| Alan W. Dunton Director | Dec 30, 2025 | 20,000 | $259.40K | Dec 30, 2025 | Stock Plan Activity |
| Joseph Todisco Officer | Dec 18, 2025 | 30,000 | $359.15K | Dec 18, 2025 | Stock Plan Activity |
| Janet Dillione BOD | Dec 9, 2025 | 34,000 | $408.00K | Dec 9, 2025 | Stock Plan Activity |
| Steven W. Lefkowitz Director | Dec 9, 2025 | 40,000 | $450.40K | Dec 9, 2025 | Open Market Purchase |
| Janet Dillione Director | Nov 24, 2025 | 73,000 | $727.93K | Nov 24, 2025 | Stock Plan Activity |
| Janet Dillione Director | Nov 14, 2025 | 30,000 | $328.20K | Nov 14, 2025 | Purchased |
| Erin Mistry Former Officer | Nov 10, 2025 | 13,543 | $148.72K | Nov 10, 2025 | Stock Plan Activity |
| Erin Mistry Former Officer | Nov 6, 2025 | 13,908 | $152.50K | Nov 6, 2025 | Stock Plan Activity |
| Alan W. Dunton Director | Sep 12, 2025 | 10,000 | $130.95K | Sep 12, 2025 | Stock plan activity |
| Joseph Todisco Officer | Sep 12, 2025 | 50,000 | $648.57K | Sep 12, 2025 | Stock Plan Activity |
| Elizabeth Hurlburt Officer | Sep 9, 2025 | 53,997 | $728.96K | Sep 9, 2025 | Stock Plan Activity |
| Kaufman Beth Zelnick Officer | Sep 9, 2025 | 50,000 | $673.00K | Sep 9, 2025 | Stock Plan Activity |
| Matthew T. David Former Officer | Sep 3, 2025 | 300,000 | $4.35M | Sep 3, 2025 | Stock Plan Activity |
| Elizabeth Hurlburt Officer | Nov 14, 2024 | 140,027 | $1.56M | Nov 14, 2024 | Stock Plan Activity |
See a number that looks wrong?